Because of the extreme genetic variability of hepatitis C virus (HCV), we analyzed whether specific HCV-genotypes are differently prone to develop resistance to linear and macrocyclic protease-inhibitors (PIs).
Cento, V., Mirabelli, C., Salpini, R., Dimonte, S., Artese, A., Costa, G., et al. (2012). HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLOS ONE, 7(7), e39652-e39652 [10.1371/journal.pone.0039652].
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors
Salpini, R;SVICHER, VALENTINA;BERTOLI, ADA;SARRECCHIA, CESARE;ANDREONI, MASSIMO;ANGELICO, MARIO;PERNO, CARLO FEDERICO;CECCHERINI SILBERSTEIN, FRANCESCA
2012-01-01
Abstract
Because of the extreme genetic variability of hepatitis C virus (HCV), we analyzed whether specific HCV-genotypes are differently prone to develop resistance to linear and macrocyclic protease-inhibitors (PIs).File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors.pdf
accesso aperto
Licenza:
Creative commons
Dimensione
2.27 MB
Formato
Adobe PDF
|
2.27 MB | Adobe PDF | Visualizza/Apri |
Questo articolo è pubblicato sotto una Licenza Licenza Creative Commons
